XML 13 R3.htm IDEA: XBRL DOCUMENT v2.3.0.15
CONSOLIDATED STATEMENTS OF OPERATIONS (USD $)
In Thousands, except Per Share data
3 Months Ended
Sep. 30, 2011
Sep. 30, 2010
Revenues:  
Research and development support$ 1,068$ 1,495
License and milestone fees1,1871,810
Clinical materials reimbursement281106
Total revenues2,5363,411
Operating Expenses:  
Research and development17,16113,425
General and administrative4,8413,364
Total operating expenses22,00216,789
Loss from operations(19,466)(13,378)
Other (expense) income, net(17)490
Loss before provision for income taxes(19,483)(12,888)
Net loss$ (19,483)$ (12,888)
Basic and diluted net loss per common share (in dollars per share)$ (0.26)$ (0.19)
Basic weighted average common shares outstanding (in shares)76,36467,944
Diluted weighted average common shares outstanding (in shares)76,36467,944